Treatment of Myasthenia Gravis in Patients with Elderly Onset at Advanced Age.

Autor: Nishikawa N; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Nagai M; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Tsujii T; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Kyaw WT; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Tanabe N; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Iwaki H; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Yabe H; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Ando R; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan., Nomoto M; Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa Tohon, Ehime, Japan.
Jazyk: angličtina
Zdroj: Japanese clinical medicine [Jpn Clin Med] 2015 Jul 23; Vol. 6, pp. 9-13. Date of Electronic Publication: 2015 Jul 23 (Print Publication: 2015).
DOI: 10.4137/JCM.S29601
Abstrakt: The number of patients with late-onset myasthenia gravis (MG) among patients ≥50 years has been increasing recently. We encountered three patients who developed elderly-onset MG at a particularly advanced age (≥80 years). All were female and positive for anti-acetylcholine receptor antibodies. About 4 years have passed since MG onset in all three patients and symptoms have been controlled without recurrence using a combination of oral low-dose prednisolone and tacrolimus. As many cases of elderly-onset MG do not require strong immunosuppression, we recommend minimum immunosuppressive treatment to avoid adverse events, particularly in patients at an advanced age of ≥80 years.
Databáze: MEDLINE
Externí odkaz: